Contemporary immunotherapy of solid tumors: From tumor-associated antigens to combination treatments

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 184-192

  Spagnoli, Giulio C ^a   Ebrahimi, Marzieh ^a,b   Iezzi, Giandomenica ^a   Mengus, Chantal ^a   Zajac, Paul ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b ROYAN INSTITUTE FOR REPRODUCTIVE BIOMEDICINE   (Iran)

Author keywords

Antibody; BCG; Cytokine; Immunological checkpoint; Immunoregulation; Solid tumor; Tumor associated antigen; Vaccine

Indexed keywords

BCG VACCINE; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE RECEPTOR; DENILEUKIN DIFTITOX; INTERLEUKIN 2; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; BLADDER CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 77749270563     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, de Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647.
2. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: Mapping the way. Nat Med (2004) 10(5): 475-480.
3. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A: Lessons from randomized phase III studies with active cancer immunotherapies-Outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine (2007) 25(Suppl 2):B97-B109.
4. Rosenthal R, Viehl CT, Guller U, Weber WP, Adamina M, Spagnoli GC, Heberer M, Zuber M: Active specifc immunotherapy phase III trials for malignant melanoma: Systematic analysis and critical appraisal. J Am Coll Surg (2008) 207(1):95-105.
5. Lucas S, Coulie PG: About human tumor antigens to be used in immunotherapy. Semin Immunol (2008) 20(5):301-307.
6. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, et al: Effcacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet (2009) 374(9686):301-314.
7. Cid-Arregui A: Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 3:67-83.
8. Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R: Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther (2004) 15(5):421-431.
9. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, et al: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 361(19):1838-1847.
10. Sheikh NA, Jones LA: CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother (2008) 57(9):1381-1390.
11. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW: Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 115(16):3670-3679.
12. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM: Placebo-controlled phase III trial of immunotherapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 24(19): 3089-3094.
13. Dendreon Corp: Dendreon reports PROVENGE regulatory and commercialization progress and future pipeline plans at analyst event. Press Release (2009): September 24.
14. Mocellin S, Mandruzzato S, Bronte V, Marincola FM: Cancer vaccines: Pessimism in check. Nat Med (2004) 10(12):1278-1279.
15. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54(3):187-207.
16. Goldman B, DeFrancesco L: The cancer vaccine roller coaster. Nat Biotechnol (2009) 27(2):129-139.
17. Bellone M, Iezzi G, Imro MA, Protti MP: Cancer immunotherapy: Synthetic and natural peptides in the balance. Immunol Today (1999) 20(10):457-462.
18. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, et al: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. Eur J Cancer (2003) 39(1):70-77.
19. Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J: Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol (2007) 27(5):451-462.
20. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med (2004) 10(9):909-915.
21. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 24(6):335-342.
22. Campoli M, Chang CC, Ferrone S: HLA class I antigen loss, tumor immune escape and immune selection. Vaccine (2002) 20(Suppl 4):A40-A45. (Pubitemid 35449404)
23. Dunn GP, Old LJ, Schreiber RD: The three Es of cancer immunoediting. Annu Rev Immunol (2004) 22:329-360.
24. Seliger B, Maeurer MJ, Ferrone S: Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 21(9): 455-464.
25. Mantovani A, Romero P, Palucka AK, Marincola FM: Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet (2008) 371(9614):771-783.
26. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, et al: Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol (2005) 174(11):6863-6871.
27. Derbinski J, Schulte A, Kyewski B, Klein L: Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol (2001) 2(11):1032-1039.
28. Gershon RK, Kondo K: Infectious immunological tolerance. Immunology (1971) 21(6):903-914.
29. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 155(3):1151-1164.
30. Colombo MP, Piconese S: Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat Rev Cancer (2007) 7(11):880-887
31. Miyara M, Sakaguchi S: Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med (2007) 13(3):108-116.
32. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S: CTLA-4 control over FOXP3+ regulatory T cell function. Science (2008) 322(5899):271-275.
33. Bluestone JA, Abbas AK: Natural versus adaptive regulatory T cells. Nat Rev Immunol (2003) 3(3):253-257.
34. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, Roncarolo MG: Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med (2002) 196(10):1335-1346.
35. Levings MK, Sangregorio R, Roncarolo MG: Human CD25+CD4+ T regulatory cells suppress naïve and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med (2001) 193(11):1295-1302.
36. Beyer M, Schultze JL: Regulatory T cells in cancer. Blood (2006) 108(3):804-811.
37. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, et al: Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 10(9):942-949.
38. Curiel TJ: Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 117(5):1167-1174.
39. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 169(5):2756-2761.
40. Chen YQ, Shi HZ, Qin XJ, Mo WN, Liang XD, Huang ZX, Yang HB, Wu C: CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion. Am J Respir Crit Care Med (2005) 172(11):1434-1439.
41. Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H: Expression of FOXP3 in non-small cell lung cancer patients is signifcantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep (2006) 15(5):1315-1319.
42. Petersen RP, Campa MJ, Sperlazza J, Conlon d, Joshi MB, Harpole DH Jr, Patz EF Jr: Tumor infltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer (2006) 107(12):2866-2872.
43. Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, Weiss ID, Galun E, Peled A: CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. J Immunol (2006) 177(10):6983-6990.
44. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 61(12):4766-4772.
45. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 168(9):4272-4276.
46. Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B: Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol (2004) 65(8):794-802.
47. Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, et al: New generation vaccine induces effective melanoma-specifc CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 177(3):1670-1678.
48. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph d, Platell C, Iacopetta B: Tumor-infltrating FOXP3+ T regulatory cells show strong prognostic signifcance in colorectal cancer. J Clin Oncol (2009) 27(2):186-192.
49. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA: Inability of a fusion protein of IL-2 and diphtheria toxin (denileukin diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother (2005) 28(6):582-592.
50. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 115(12):3623-3633.
51. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin d, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 34(2):336-344.
52. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le CA, Zitvogel L, Chauffert B: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2007) 56(5):641-648.
53. Mellor AL, Munn DH: IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 4(10):762-774.
54. Puccetti P, Grohmann U: IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-κB activation. Nat Rev Immunol (2007) 7(10):817-823.
55. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP: Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 206(8):1717-1725.
56. Beck KE, Blansfeld JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte- associated antigen 4. J Clin Oncol (2006) 24(15):2283-2289.
57. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, et al: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 30(8):825-830.
58. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA (2003) 100(14): 8372-8377.
59. Korman AJ, Peggs KS, Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 90:297-339.
60. Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A: Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther (2006) 5(8):1975-1985.
61. Murugaiyan G, Agrawal R, Mishra GC, Mitra D, Saha B: Differential CD40/CD40L expression results in counteracting antitumor immune responses. J Immunol (2007) 178(4):2047-2055.
62. Tang Y, Zhang L, Yuan J, Akbulut H, Maynard J, Linton PJ, Deisseroth A: Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. Blood (2004) 104(9):2704-2713.
63. Tang Y, Akbulut H, Maynard J, Petersen L, Fang X, Zhang WW, Xia X, Koziol J, Linton PJ, Deisseroth A: Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J Immunol (2006) 177(8):5697-5707.
64. Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK: Reversing tumor immune suppression with intratumoral IL-12: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infltration of CD8+ T effectors. J Immunol (2006) 177(10):6962-6973.
65. King IL, Segal BM: Cutting edge: IL-12 induces CD4+CD25-T cell activation in the presence of T regulatory cells. J Immunol (2005) 175(2):641-645.
66. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 309(5739): 1380-1384.
67. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA: Tumor antigen-specifc CD8 T cells infltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114(8):1537-1544.
68. Blank C, Mackensen A: Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2007) 56(5):739-745.
69. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF: Programmed death 1 signaling on chronic myeloid leukemia-specifc T cells results in T-cell exhaustion and disease progression. Blood (2009) 114(8):1528-1536.
70. Zhang L, Gajewski TF, Kline J: PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood (2009) 114(8):1545-1552.
71. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfeld LH, Weiner L: Immunogenicity and antitumor effects of vaccination with peptide vaccine +/-granulocyte-monocyte colony-stimulating factor and/or IFN-α2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group phase II trial E1696. Clin Cancer Res (2009) 15(4):1443-1451.
72. Reed SG, Bertholet S, Coler RN, Friede M: New horizons in adjuvants for vaccine development. Trends Immunol (2009) 30(1):23-32.
73. Schubert C: Boosting our best shot. Nat Med (2009) 15(9): 984-988.
74. Trinchieri G, Sher A: Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7(3):179-190.
75. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989) 54(Pt 1):1-13.
76. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P: CpG are effcient adjuvants for specifc CTL induction against tumor antigen-derived peptide. J Immunol (2002) 168(3):1212-1218.
77. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, Salcedo R, Yu H: Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res (2009) 69(6): 2497-2505.
78. Schon MP, Schon M: TLR7 and TLR8 as targets in cancer therapy. Oncogene (2008) 27(2):190-199.
79. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, Cruz CM, Angiulli A, Angiulli F, Ritter E, Holman RM, et al: Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol (2008) 181(1):776-784.
80. Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, et al: Induction of immune responses and clinical effcacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol (2008) 26(27):4418-4425.
81. 26-35 peptide encapsulated into virosomes in vitro. Vaccine (2005) 23(48-49):5572-5582.
82. Bioley G, dousset C, Yeh A, dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D: Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res (2009) 15(13):4467-4474.
83. Feder-Mengus C, Schultz-Thater E, Oertli D, Marti WR, Heberer M, Spagnoli GC, Zajac P: Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specifc CD4+ and CD8+ T cell responses. Hum Gene Ther (2005) 16(3):348-360.
84. Zajac P, Oertli D, Marti W, Adamina M, Bolli M, Guller U, Noppen C, Padovan E, Schultz-Thater E, Heberer M, Spagnoli G. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther (2003) 14(16):1497-1510.
85. Dudley ME, Rosenberg SA: Adoptive cell transfer therapy. Semin Oncol (2007) 34(6):524-531.
86. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26(32):5233-5239.
87. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol (2009) 21(2):233-240.
88. Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tuting T: Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res (2009) 69(15):6265-6274.
89. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-dreese FA, dellemijn TA, Antony PA, Spiess PJ, Palmer dC, Heimann dM, et al: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 198(4):569-580.
90. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 314(5796):126-129.
91. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 8(4):299-308.
92. Johnson LA, Morgan RA, dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 114(3):535-546.
93. Cesana GC, deRaffele G, Cohen S, Moroziewicz d, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL: Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol (2006) 24(7):1169-1177.
94. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A: Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: Association with clinical stage. Clin Cancer Res (2009) 15(12):4085-4094.
95. Schluns KS, Lefrancois L: Cytokine control of memory T-cell development and survival. Nat Rev Immunol (2003) 3(4): 269-279.
96. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, et al: Clinical and biological effcacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: A phase IIa trial. Clin Cancer Res (2009) 15(6):2123-2129.
97. Elsaesser H, Sauer K, Brooks DG: IL-21 is required to control chronic viral infection. Science (2009) 324(5934):1569-1572.
98. Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M: IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science (2009) 324(5934):1576-1580.
99. Yi JS, Du M, Zajac AJ: A vital role for interleukin-21 in the control of a chronic viral infection. Science (2009) 324(5934): 1572-1576.
100. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer dC, Tagaya Y, et al: IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA (2004) 101(7):1969-1974.
101. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity (2001) 14(2):105-110.
102. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res (2004) 10(17):5650-5655.
103. Musolino A, Naldi N, Bortesi B, Pezzuolo d, Capelletti M, Missale G, Laccabue d, Zerbini A, Camisa R, Bisagni G, Neri TM, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical effcacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 26(11):1789-1796.
104. Taylor RJ, Chan SL, Wood A, Voskens CJ, Wolf JS, Lin W, Chapoval A, Schulze DH, Tian G, Strome SE: FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother (2009) 58(7):997-1006.
105. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins dM, Fintak PA, dela RC et al: Concurrent trastuzumab and HER2/neu-specifc vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 27(28): 4685-4692.
106. Kono H, Rock KL: How dying cells alert the immune system to danger. Nat Rev Immunol (2008) 8(4):279-289.
107. Bianchi ME, Manfredi AA: Immunology. Dangers in and out. Science (2009) 323(5922):1683-1684.
108. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y, Hangai S, Koshiba R, Savitsky D et al: HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 462(7269): 99-103.
109. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier d, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2007) 13(1):54-61. (Pubitemid 46067386)
110. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest (2008) 118(6):1991-2001.
111. Kepp O, Tesniere A, Zitvogel L, Kroemer G: The immunogenicity of tumor cell death. Curr Opin Oncol (2009) 21(1):71-76.
112. Alleva LM, Budd AC, Clark IA: Systemic release of high mobility group box 1 protein during severe murine infuenza. J Immunol (2008) 181(2):1454-1459.
113. Wang H, Ward MF, Fan XG, Sama AE, Li W: Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol (2006) 19(1):3-9.
114. Kirn DH, Thorne SH: Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 9(1):64-71.
115. Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA: An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol (2009) 56(2):247-256.
116. Bevers RF, Kurth KH, Schamhart DH: Role of urothelial cells in BCG immunotherapy for superfcial bladder cancer. Br J Cancer (2004) 91(4):607-612.
117. decobert M, Larue H, Bergeron A, Harel F, Pfster C, Rousseau F, Lacombe L, Fradet Y: Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superfcial bladder cancer. J Urol (2006) 175(4):1506-1511.
118. Saban MR, Simpson C, Davis C, Wallis G, Knowlton N, Frank MB, Centola M, Gallucci RM, Saban R: Discriminators of mouse bladder response to intravesical bacillus Calmette-Guerin (BCG). BMC Immunol (2007) 8:6.
119. Zaharoff DA, Hoffman BS, Hooper HB, Benjamin CJ Jr, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW: Intravesical immunotherapy of superfcial bladder cancer with chitosan/ interleukin-12. Cancer Res (2009) 69(15):6192-6199.
120. Nistico P, Capone I, Palermo B, del Bd, Ferraresi V, Moschella F, Arico E, Valentini M, Bracci L, Cognetti F, Ciccarese M, et al: Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer (2009) 124(1): 130-139.
121. Cheever MA: Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 222:357-368.
122. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ Jr, Bankert RB, Bernstein SH: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specifc T-cell response in patients with follicular lymphoma: Support for a "vaccinal effect" of rituximab. Blood (2009) 113(16):3809-3812.
123. Weiner LM, Dhodapkar MV, Ferrone S: Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 373(9668):1033-1040.
124. Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG: Translational Research Working Group developmental pathway for immune response modifers. Clin Cancer Res (2008) 14(18):5692-5699.